Pamela McCombe
Pamela McCombe
Verified email at
Cited by
Cited by
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...
The Lancet 380 (9856), 1829-1839, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...
The Lancet 380 (9856), 1819-1828, 2012
Gender differences in autoimmune disease
ST Ngo, FJ Steyn, PA McCombe
Frontiers in neuroendocrinology 35 (3), 347-369, 2014
Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases
PA MCOMBE, JD Pollard, JG McLeod
Brain 110 (6), 1617-1630, 1987
Effects of gender in amyotrophic lateral sclerosis
PA McCombe, RD Henderson
Gender medicine 7 (6), 557-570, 2010
Apoptosis in the nervous system in experimental allergic encephalomyelitis
MP Pender, KB Nguyen, PA McCombe, JFR Kerr
Journal of the neurological sciences 104 (1), 81-87, 1991
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Sexual dimorphism in autoimmune disease
PA McCombe, JM Greer, IR Mackay
Current molecular medicine 9 (9), 1058-1079, 2009
The role of immune and inflammatory mechanisms in ALS
P A McCombe, R D Henderson
Current molecular medicine 11 (3), 246-254, 2011
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms
JM Greer, PA McCombe
Journal of neuroimmunology 234 (1-2), 7-18, 2011
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of neurology 77 (3), 425-435, 2015
The effect of ageing on human lymphocyte subsets: comparison of males and females
J Yan, JM Greer, R Hull, J D O'Sullivan, RD Henderson, SJ Read, ...
Immunity & Ageing 7 (1), 1-10, 2010
Apoptosis of αβ T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: its possible implications for recovery and acquired tolerance
MP Pender, PA McCombe, G Yoong, KB Nguyen
Journal of autoimmunity 5 (4), 401-410, 1992
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses
DH Spector, K Smith, T Padgett, P McCombe, D Roulland-Dussoix, ...
Cell 13 (2), 371-379, 1978
Apoptotic elimination of Vβ8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vβ8 …
Z Tabi, PA McCombe, MP Pender
European journal of immunology 24 (11), 2609-2617, 1994
Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy
JD Pollard, PA McCombe, J Baverstock, PA Gatenby, JG McLeod
Journal of neuroimmunology 13 (2), 123-134, 1986
The system can't perform the operation now. Try again later.
Articles 1–20